Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

SRP-1001

Oligonucleotide (siRNA) · Gene silencing: DUX4 · developed by Sarepta Therapeutics

Phase 1/2 Most advanced trial
SRPT Developer
1 Registered trials

What is SRP-1001?

SRP-1001 (ARO-DUX4) is an intravenously infused agent studied in facioscapulohumeral muscular dystrophy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Oligonucleotide (siRNA)
Targets
DUX4
Mechanism
Gene silencing: DUX4
Therapy area
Musculoskeletal
Developer
Sarepta Therapeutics, Inc. (SRPT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06131983 Phase 1/2 Muscular Dystrophy, Facioscapulohumeral Enrolling by invitation SRPT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Muscular Dystrophy, Facioscapulohumeral

More from Sarepta Therapeutics

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SRPT page.

Follow SRPT, the company behind SRP-1001

See SRPT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SRPT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.